IC87201 | nNOS-PDZ/PSD-95-PDZ inhibitor | CAS#866927-10-8

MedKoo Cat#: 526932 | Name: IC87201

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IC87201 is a nNOS-PDZ/PSD-95-PDZ inhibitor. IC87201 showed great promise in cellular experiments and animal models of ischemic stroke and pain. IC87201 inhibited the in vitro binding of nNOS with PSD95, without inhibiting nNOS catalytic activity. nNOS-PSD95 interaction is important in maintaining hypersensitivity in acute and chronic pain. Disruption of the nNOS-PSD95 interaction provides a novel approach to obtain selective anti-hyperalgesic compounds.

Chemical Structure

IC87201

CAS#866927-10-8

Theoretical Analysis

MedKoo Cat#: 526932

Name: IC87201

CAS#: 866927-10-8

Chemical Formula: C13H10Cl2N4O

Exact Mass: 308.0232

Molecular Weight: 309.15

Elemental Analysis: C, 50.51; H, 3.26; Cl, 22.93; N, 18.12; O, 5.18

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,250.00	2 Weeks
1g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

IC87201; IC-87201; IC 87201.

IUPAC/Chemical Name

2-((1H-Benzo[d] [1,2,3]triazol-5-ylamino) methyl)-4,6-dichlorophenol

InChi Key

QEHVTUCLCBXQIC-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H10Cl2N4O/c14-8-3-7(13(20)10(15)4-8)6-16-9-1-2-11-12(5-9)18-19-17-11/h1-5,16,20H,6H2,(H,17,18,19)

SMILES Code

OC1=C(Cl)C=C(Cl)C=C1CNC2=CC=C(NN=N3)C3=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.

In vitro activity:

The resulting compound, IC87201, 2-[(1H-benzotriazol-5-ylamino)-methyl]-4,6-dichloro-phenol (Figure 1A), showed dose-dependent inhibition of nNOS–PSD95 binding (Figure 1B) with an IC50 of 31 µM (95% confidence interval 25–38 µM, n= 5). Reference: Br J Pharmacol. 2009 Sep;158(2):494-506. https://pubmed.ncbi.nlm.nih.gov/19732061/

In vivo activity:

IC87201 and ZL006, but not ZL007, suppressed phase 2 of formalin-evoked pain behavior and decreased the number of formalin-induced Fos-like immunoreactive cells in spinal dorsal horn regions associated with nociceptive processing. Reference: Neuroscience. 2017 May 4;349:303-317. https://pubmed.ncbi.nlm.nih.gov/28285942/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	97.04
	DMSO	29.0	93.81
	DMSO:PBS (pH 7.2) (1:3)	0.3	0.81
	Ethanol	1.0	3.23

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 309.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Florio SK, Loh C, Huang SM, Iwamaye AE, Kitto KF, Fowler KW, Treiberg JA, Hayflick JS, Walker JM, Fairbanks CA, Lai Y. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br J Pharmacol. 2009 Sep;158(2):494-506. doi: 10.1111/j.1476-5381.2009.00300.x. PMID: 19732061; PMCID: PMC2757689. 2. Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience. 2017 May 4;349:303-317. doi: 10.1016/j.neuroscience.2017.02.055. Epub 2017 Mar 8. PMID: 28285942; PMCID: PMC5518314. 3. Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. Epub 2016 Feb 22. PMID: 26909849; PMCID: PMC4808404.

In vitro protocol:

In vivo protocol:

1. Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience. 2017 May 4;349:303-317. doi: 10.1016/j.neuroscience.2017.02.055. Epub 2017 Mar 8. PMID: 28285942; PMCID: PMC5518314. 2. Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. Epub 2016 Feb 22. PMID: 26909849; PMCID: PMC4808404.

1: Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. PubMed PMID: 26909849; PubMed Central PMCID: PMC4808404. 2: Bach A, Pedersen SW, Dorr LA, Vallon G, Ripoche I, Ducki S, Lian LY. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157. doi: 10.1038/srep12157. PubMed PMID: 26177569; PubMed Central PMCID: PMC4503980. 3: Doucet MV, O'Toole E, Connor T, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. Neuroscience. 2015 Aug 20;301:421-38. doi: 10.1016/j.neuroscience.2015.06.004. PubMed PMID: 26071957. 4: Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. 2015 Oct;97:464-75. doi: 10.1016/j.neuropharm.2015.05.038. PubMed PMID: 26071110; PubMed Central PMCID: PMC4539046. 5: Hu W, Guan LS, Dang XB, Ren PY, Zhang YL. Small-molecule inhibitors at the PSD-95/nNOS interface attenuate MPP+-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction. Neurochem Int. 2014 Dec;79:57-64. doi: 10.1016/j.neuint.2014.10.005. PubMed PMID: 25452082. 6: Doucet MV, Levine H, Dev KK, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology. 2013 Jul;38(8):1575-84. doi: 10.1038/npp.2013.57. PubMed PMID: 23446451; PubMed Central PMCID: PMC3682152. 7: Florio SK, Loh C, Huang SM, Iwamaye AE, Kitto KF, Fowler KW, Treiberg JA, Hayflick JS, Walker JM, Fairbanks CA, Lai Y. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br J Pharmacol. 2009 Sep;158(2):494-506. doi: 10.1111/j.1476-5381.2009.00300.x. PubMed PMID: 19732061; PubMed Central PMCID: PMC2757689.